Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 12, 2016. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a single transaction involving the acquisition of ordinary shares.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares under ShareReward Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Share Price | £16.7127 |
| Total Volume | 14 Ordinary shares |
| Transaction Date | July 11, 2016 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports a routine acquisition of 14 shares (7 partnership shares and 7 matching shares) by a Person Discharging Managerial Responsibilities (PDMR).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a specific share transaction.
Important Facts for Investors
- Insider Identity: The transaction was executed by Dr. P J T Vallance, President of Pharmaceuticals R&D.
- Transaction Nature: The purchase was made under the Company's ShareReward Plan, consisting of partnership and matching shares.
- Market Data: The transaction occurred on the London Stock Exchange (XLON) at a price of £16.7127 per share.
- Scope Limitation: This document does not contain financial performance data; investors should refer to Form 20-F for comprehensive financial results.